Edition:
United States

Sumitomo Dainippon Pharma Co Ltd (4506.T)

4506.T on Tokyo Stock Exchange

1,667JPY
18 Dec 2017
Change (% chg)

¥31 (+1.89%)
Prev Close
¥1,636
Open
¥1,650
Day's High
¥1,671
Day's Low
¥1,641
Volume
851,000
Avg. Vol
1,399,627
52-wk High
¥2,134
52-wk Low
¥1,397

Chart for

About

Sumitomo Dainippon Pharma Co., Ltd., formerly Dainippon Sumitomo Pharma Co.,Ltd., is a pharmaceutical company. The Japan division manufactures and sells ethical and general use drugs. The North America division manufactures, develops, purchases and sells ethical drugs through its consolidated subsidiaries. The China division... (more)

Overall

Beta: 0.78
Market Cap(Mil.): ¥650,964.62
Shares Outstanding(Mil.): 397.90
Dividend: 11.00
Yield (%): 1.10

Financials

  Industry Sector
P/E (TTM): -- 32.20 16.04
EPS (TTM): -- -- --
ROI: -- 15.06 34.69
ROE: -- 16.55 15.46

BRIEF-Sunovion Receives FDA Approval for Lonhala Magnair Inhalation Solution to Treat COPD

* SUNOVION RECEIVES FDA APPROVAL FOR LONHALA MAGNAIR INHALATION SOLUTION TO TREAT COPD

Dec 05 2017

BRIEF-Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda (Lurasidone Hydrochloride) in Europe

* Says it and Angelini S.p.A announced today that the companies have formed a partnership with the goal to expand availability in Europe of Latuda®, an atypical antipsychotic which was created by the co

Nov 21 2017

BRIEF-Sumitomo Dainippon Pharma and Poxel announce strategic partnership for development and commercialization of Imeglimin

* Says it signed an agreement with Poxel SA on Oct. 30, for the development and commercialization of Imeglimin, an investigational therapeutic agent for type 2 diabetes, in Japan, China, South Korea, Taiwan and nine other Southeast Asian countries

Oct 30 2017

BRIEF-Poxel and Sumitomo Dainippon Pharma in partnership to develop and sell Imeglimin in Asia

* SUMITOMO DAINIPPON PHARMA AND POXEL ANNOUNCE STRATEGIC PARTNERSHIP FOR DEVELOPMENT AND COMMERCIALIZATION OF IMEGLIMIN, AN INVESTIGATIONAL THERAPEUTIC AGENT FOR TYPE 2 DIABETES, IN JAPAN, CHINA AND ELEVEN OTHER ASIAN COUNTRIES

Oct 30 2017

BRIEF-Kitasato Institute and Sumitomo Dainippon Pharma signs joint drug discovery research agreement

* Says it and the Kitasato Institute have signed a joint drug discovery research agreement for infections caused by bacteria with antimicrobial resistance (AMR)

Oct 24 2017

BRIEF-R&I affirms Sumitomo Dainippon Pharma's rating at "A" and announces stable outlook -R&I

* Says Rating and Investment Information, Inc. (R&I) affirmed the company's rating at "A" -R&I

Oct 03 2017

BRIEF-Sumitomo Dainippon Pharma to offer early-retirement program

* Says it will offer an early-retirement program to employees, who are above 45 years old and continuous service of above 5 years as of March 31, 2018, and employees is members of manufacturing division as of Sept. 1, 2016

Sep 27 2017

BRIEF-Sumitomo Dainippon Pharma U.S.-based unit enters agreement to divest asthma and allergy products to Covis pharma

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. has entered into a definitive agreement to divest the U.S. market rights of Sunovion’s three ciclesonide products to Covis Pharma B.V. on July 13(US Eastern Time)

Jul 13 2017

BRIEF- Sumitomo Dainippon Pharma unit Sunovion announces FDA acceptance for review of new drug application resubmission for SUN-101

* Says its U.S.-based unit Sunovion Pharmaceuticals Inc. announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the New Drug Application for SUN-101/eFlow® (glycopyrrolate) for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD)

Jul 02 2017

BRIEF- Sumitomo Chemical unit Sumitomo Dainippon Pharma announces unblinding of phase 3 study of Napabucasin

* Says its unit Sumitomo Dainippon Pharma Co Ltd announced today that the company decided to unblind the BRIGHTER study, a phase 3 global study in patients with gastric and gastro-esophageal junction (GEJ) cancer of napabucasin, an investigational cancer stemness inhibitor, based on a recommendation by the study’s independent Data and Safety Monitoring Board (DSMB), following a pre- specified interim analysis

Jun 25 2017

Earnings vs. Estimates